EVALUATION OF MULTIPLE HEMOSTATIC PARAMETERS FOLLOWING DOSING OF RECOMBINANT
EVALUATION OF MULTIPLE HEMOSTATIC PARAMETERS FOLLOWING DOSING OF RECOMBINANT
批准号:
8166551
负责人:
Donald Fitzpatrick Brophy
金额:
$0.02万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-12-01 至 2010-06-30
关键词:
Biological AssayBlood Coagulation Factor VIIBlood PlateletsCoagulation ProcessComputer Retrieval of Information on Scientific Projects DatabaseDoseEvaluationFactor VIIIFibrin fragment DFundingGenerationsGrantHemostatic AgentsIn VitroInstitutionPatientsRecombinantsResearchResearch PersonnelResourcesSourceThrombelastographyThrombinTimeUnited States National Institutes of Healthantithrombin III-protease complexinhibitor/antagonistprothrombin fragment 1.2
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Hypothesis: Following dosing of recombinant Factor Vila 90 mcg/kg in hemophiliacs, platelet contractile force (PC F), clot elastic modulus (CEM) and thrombin generation time (TGT) normalize. These parameters will change comparably to the following established clotting parameters: Thromboelastography (TEG), Rotational Thromboelastography (ROTEG), in vitro thrombin generation, thrombin-antithrombin complex, Prothrombin Fragment 1.2, Factor VII activity and D-dimer.
Specific Aims:
a. Document baseline TGT, PCF and CEM abnormalities in hemophiliacs with and without spontaneous factor VIII inhibitors. Secondly, document clotting deficiencies utilizing the TEG4!> and ROTEG4!> clotting parameters as well as assays detecting thrombin generation, TAT, Prothrombin Fragment 1.2, Factor 7 activity and D-dimer.
b. Establish the extent by which TGT, PCF and CEM normalize in the above patients following the administration of rFVlla 90 mcg/kg. Secondly, document the extent by which clotting deficiencies normalize utilizing the TEG4!> and ROTEG4!> clotting parameters, as well as assays detecting thrombin generation, TAT, Prothrombin Fragment 1.2, Factor 7 activity and D-dimer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vitamin C, Sepsis and Coagulopathy: An Ancillary Study of the CITRIS-ALI Trial
-
批准号:8956642
-
项目类别:
-
资助金额:$44.3万
-
财政年份:2015
-
负责人:Donald Fitzpatrick Brophy
-
依托单位:
DEVELOPMENT OF A NOVEL WHOLE BLOOD COAGULATION ASSAY
-
批准号:7605019
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2006
-
负责人:Donald Fitzpatrick Brophy
-
依托单位:
DEVELOPMENT OF A NOVEL WHOLE BLOOD COAGULATION ASSAY
-
批准号:7375159
-
项目类别:
-
资助金额:$2.37万
-
财政年份:2005
-
负责人:Donald Fitzpatrick Brophy
-
依托单位:
DEVELOPMENT OF A NOVEL WHOLE BLOOD COAGULATION ASSAY
-
批准号:7201521
-
项目类别:
-
资助金额:$0.56万
-
财政年份:2004
-
负责人:Donald Fitzpatrick Brophy
-
依托单位: